ASH 2017 | The Hokusai VTE-Cancer Study: objectives and design
What were the objectives of the Hokusai venous thromboembolism (VTE)-Cancer Study? In this interview, Harry Buller, MD, PhD, of the Academic Medical Centre, Amsterdam, Netherlands, highlights the major components, objectives and findings of the trial (NCT02073682), which compared two regimens, subcutaneous injection of low-molecular-weight heparin (LMWH) and oral administration of edoxaban. Prof. Buller discusses various elements of the trial, including focusing on the composite of first recurrence or the first major bleed from VTE and continuing treatment beyond 6 months. Describing the LMWH treatment as noninferior to oral edoxaban, Prof. Buller explains the advantages of edoxaban for patients with cancer-associated VTE. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Get great new content delivered to your inboxSign up